QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)

Adaptimmune Therapeutics (ADAP) News Today

$1.57
-0.04 (-2.48%)
(As of 02/29/2024 ET)
SourceHeadline
investing.com logoAdaptimmune reappoints Cintia Piccina as chief commercial officer
investing.com - February 29 at 10:08 AM
MarketBeat logoAdaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update
americanbankingnews.com - February 29 at 1:46 AM
finance.yahoo.com logoADAP Apr 2024 1.500 put
finance.yahoo.com - February 28 at 4:07 AM
finance.yahoo.com logoAdaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
finance.yahoo.com - February 27 at 12:15 PM
finance.yahoo.com logoADAP Apr 2024 2.000 call
finance.yahoo.com - February 26 at 1:41 AM
MarketBeat logoAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.38
americanbankingnews.com - February 25 at 2:52 AM
wsj.com logoAdaptimmune Therapeutics PLC ADR
wsj.com - February 24 at 5:50 PM
finance.yahoo.com logoADAP Sep 2024 2.000 call
finance.yahoo.com - February 23 at 11:02 AM
finance.yahoo.com logoADAP Jun 2024 1.000 call
finance.yahoo.com - February 22 at 6:36 PM
finance.yahoo.com logoADAP Apr 2024 1.500 call
finance.yahoo.com - February 22 at 6:36 PM
finance.yahoo.com logoAdaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
finance.yahoo.com - February 21 at 8:23 PM
finance.yahoo.com logo15 Top Performing European Stocks So Far in 2024
finance.yahoo.com - February 16 at 6:42 AM
finance.yahoo.com logoAdaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
finance.yahoo.com - February 13 at 7:56 PM
marketbeat.com logoAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Up 8.5%
marketbeat.com - February 6 at 2:01 PM
marketbeat.com logoAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.04
marketbeat.com - February 5 at 11:54 AM
seekingalpha.com logoAdaptimmune: Drug Approval Now Imminent?
seekingalpha.com - February 2 at 12:49 PM
msn.com logoAdaptimmune’s T-Cell Therapy Priority Review by FDA
msn.com - February 1 at 8:50 AM
marketwatch.com logoAdaptimmune Therapeutics Gets FDA Priority Review Approval for Sarcoma License Application
marketwatch.com - January 31 at 7:46 PM
finance.yahoo.com logoAdaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
finance.yahoo.com - January 31 at 7:46 PM
marketbeat.com logoAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Up 8.6%
marketbeat.com - January 31 at 12:43 PM
finance.yahoo.com logoBaillie Gifford Increases Stake in Adaptimmune Therapeutics PLC
finance.yahoo.com - January 30 at 5:42 PM
investing.com logoAdaptimmune Therapeutics Plc (ADAP)
investing.com - January 30 at 12:42 PM
markets.businessinsider.com logoMaintaining Buy Rating on Leap Therapeutics: Promising DKN-01 Trials and Undervalued Market Potential
markets.businessinsider.com - January 26 at 5:19 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Arcus Biosciences (RCUS) and Zai Lab (ZLAB)
markets.businessinsider.com - January 24 at 8:54 AM
finance.yahoo.com logoAdaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
finance.yahoo.com - January 17 at 9:39 AM
marketbeat.com logoAdaptimmune Therapeutics plc (NASDAQ:ADAP) CEO Sells $10,033.80 in Stock
marketbeat.com - January 12 at 6:51 PM
msn.com logoEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
msn.com - January 5 at 1:28 PM
finance.yahoo.com logoAdaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:42 AM
msn.com logoEuropean Equities Traded in the US as American Depositary Receipts Decline Thursday
msn.com - December 28 at 2:07 PM
markets.businessinsider.com logoStrategic Focus and Promising Clinical Trials Bolster Buy Rating for Leap Therapeutics
markets.businessinsider.com - December 16 at 8:45 PM
finance.yahoo.com logoPositive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year
finance.yahoo.com - December 7 at 9:56 AM
finance.yahoo.com logoAdaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
finance.yahoo.com - December 6 at 8:08 AM
benzinga.com logoAdaptimmune Therapeutics Stock (NASDAQ:ADAP) Earnings Dates and Earning Calls
benzinga.com - December 3 at 1:20 PM
benzinga.com logoAdaptimmune Therapeutics Stock (NASDAQ:ADAP) Dividends: History, Yield and Dates
benzinga.com - December 3 at 1:20 PM
markets.businessinsider.com logoBuy Rating Affirmed for Adaptimmune on Strong Pipeline Developments and Market Expansion Potential
markets.businessinsider.com - December 2 at 8:03 AM
finanznachrichten.de logoAdaptimmune Therapeutics PLC: Adaptimmune Receives Transfer of IND for Lete-cel Program
finanznachrichten.de - November 29 at 9:03 AM
finance.yahoo.com logoAdaptimmune Receives Transfer of IND for Lete-cel Program
finance.yahoo.com - November 29 at 9:03 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Vincerx Pharma Inc (VINC) and Pharvaris (PHVS)
markets.businessinsider.com - November 16 at 11:51 PM
finanznachrichten.de logoT-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
finanznachrichten.de - November 15 at 2:23 AM
markets.businessinsider.com logoAnalysts Conflicted on These Healthcare Names: Harpoon Therapeutics (HARP), Disc Medicine (IRON) and Rain Therapeutics (RAIN)
markets.businessinsider.com - November 14 at 4:23 PM
finance.yahoo.com logoAdaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
finance.yahoo.com - November 13 at 4:34 PM
insidermonkey.com logoAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript
insidermonkey.com - November 13 at 9:05 AM
finance.yahoo.com logoForecast: Analysts Think Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Business Prospects Have Improved Drastically
finance.yahoo.com - November 9 at 7:58 AM
finance.yahoo.com logoAdaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
finance.yahoo.com - November 8 at 10:46 AM
finance.yahoo.com logoAdaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing
finance.yahoo.com - November 7 at 11:25 PM
morningstar.com logoAdaptimmune Therapeutics PLC ADR ADAP
morningstar.com - November 7 at 1:16 AM
finance.yahoo.com logoAdaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
finance.yahoo.com - October 31 at 10:08 AM
finance.yahoo.com logoAdaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
finance.yahoo.com - October 31 at 10:08 AM
msn.com logoAdaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights
msn.com - October 27 at 7:35 PM
markets.businessinsider.com logoHold Rating on Adaptimmune Therapeutics Amid Phase I SURPASS Trial Results: Insights on Efficacy, Safety Concerns, and Future Expectations
markets.businessinsider.com - October 26 at 12:36 AM
Get Adaptimmune Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.



ADAP Media Mentions By Week

ADAP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADAP
News Sentiment

0.46

0.60

Average
Medical
News Sentiment

ADAP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADAP Articles
This Week

12

2

ADAP Articles
Average Week

Get Adaptimmune Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ADAP) was last updated on 2/29/2024 by MarketBeat.com Staff